ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Data as of Aug 20, 2026, from SEC Form 4 filings.

Net insider selling (90d)Watch ARWR

See up to 3 months of ARWR. The 7-day demo opens the 1M and 3M ranges and puts ARWR on your watchlist.

Latest ARWR insider trades

Adeoye Y. Olukotun - Director
Open-market sale$174K
Aug 18, 2026
Michael S. Perry - Director

About ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

ARROWHEAD PHARMACEUTICALS, INC. is an SEC registrant, filing under CIK 0000879407, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.

Sector: Health Care

SEC filings for ARWR on EDGAR

ARWR Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Open-market sale	2	13,600	$1.19M

ARWR insider transactions (Form 4)

25 Form 4 filings on record, the earliest from Dec 18, 2024, newest first.

Date	Insider	Transaction	Security	Shares	Price	Value
Aug 18, 2026	Adeoye Y. Olukotun - Director	Open-market sale	Common Stock	2,000	$86.96	$174K
Aug 18, 2026	Michael S. Perry - Director	Open-market sale	Common Stock	11,600	$87.30^{footnote F1}	$1.01M
Footnote F1 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR
Jun 15, 2026	Matthew Gregory Cohen - Director	Grant or award	Common Stock	11,882^{footnote F1}	$0.00	-
Footnote F1 (shares): Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years.
May 12, 2026	Hongbo Lu - Director	Open-market sale	Common Stock	2,970	$76.88	$228K
Apr 22, 2026	Daniel Joseph Apel - Officer	Open-market sale	Common Stock	3,208^{footnote F2}	$70.11^{footnote F3}	$225K
Apr 22, 2026	Daniel Joseph Apel - Officer	Open-market sale	Common Stock	1,157^{footnote F2}	$70.45^{footnote F5}	$82K
Apr 22, 2026	Daniel Joseph Apel - Officer	Open-market sale	Common Stock	8,730^{footnote F2}	$71.92^{footnote F6}	$628K
Footnote F2 (shares): Partial disposition of shares to satisfy tax withholding obligations. Footnote F3 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F5 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F6 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $71.55 to $71.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR
Apr 23, 2026	James C. Hamilton - Officer	Open-market sale	Common Stock	10,000	$75.00^{footnote F2}	$750K
Footnote F2 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR
Mar 5, 2026	James C. Hamilton - Officer	Open-market sale	Common Stock	10,000	$64.19^{footnote F2}	$642K
Footnote F2 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.80 to $64.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR
Dec 12, 2025	Christopher Richard Anzalone - Officer	Grant or award	Common Stock	180,000^{footnote F1}	$0.00	-
Dec 15, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	100,532^{footnote F3}	$68.67^{footnote F4}	$6.90M
Dec 15, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	21,321^{footnote F3}	$69.28^{footnote F5}	$1.48M
Dec 15, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	8,147^{footnote F3}	$69.96^{footnote F6}	$570K
Dec 16, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	8,416^{footnote F3}	$60.51^{footnote F7}	$509K
Dec 16, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	10,963^{footnote F3}	$61.25^{footnote F8}	$671K
Dec 16, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	14,095^{footnote F3}	$62.12^{footnote F9}	$876K
Dec 16, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	8,476^{footnote F3}	$62.94^{footnote F10}	$533K
Dec 16, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	6,661^{footnote F3}	$64.29^{footnote F11}	$428K
Dec 16, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	1,000^{footnote F3}	$64.96^{footnote F12}	$65K
Dec 16, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	1,300^{footnote F3}	$65.77^{footnote F13}	$86K
Dec 16, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	166^{footnote F3}	$66.77^{footnote F14}	$11K
Dec 16, 2025	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	3,221^{footnote F3}	$67.87^{footnote F15}	$219K
Footnote F1 (shares): Represents shares underlying restricted stock units with a grant date December 12, 2025, which will vest in four equal annual installments. Footnote F3 (shares): Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4. Footnote F4 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.28 to $69.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F5 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.01 to $69.75, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F6 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.83 to $70.32, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F7 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $59.73 to $60.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F8 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.79 to $61.68, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F9 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.72 to $62.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F10 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.62 to $63.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F11 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.56 to $64.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F12 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.81 to $65.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F13 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.63 to $65.96, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F14 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.70 to $66.88, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR Footnote F15 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.70 to $68.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR
Nov 28, 2025	Mauro Ferrari - Director	Open-market sale	Common Stock	8,750	$56.39	$493K
Oct 1, 2025	James C. Hamilton - Officer	Open-market sale	Common Stock	20,000	$35.00^{footnote F2}	$700K
Footnote F2 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR
Sep 12, 2025	James C. Hamilton - Officer	Open-market sale	Common Stock	15,000	$30.00	$450K
Sep 2, 2025	James C. Hamilton - Officer	Open-market sale	Common Stock	15,000	$25.00	$375K
Aug 13, 2025	James C. Hamilton - Officer	Open-market sale	Common Stock	611	$20.00	$12K
Aug 15, 2025	James C. Hamilton - Officer	Open-market sale	Common Stock	9,389	$20.00	$188K
Dec 27, 2024	Adeoye Y. Olukotun - Director	Open-market sale	Common Stock	2,850	$20.00	$57K
Dec 23, 2024	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	12,563	$19.59	$246K
Dec 18, 2024	Victoria Vakiener - Director	Grant or award	Common Stock	16,733	$22.99	$385K
Dec 18, 2024	Hongbo Lu - Director	Grant or award	Common Stock	16,733	$22.99	$385K
Dec 18, 2024	William D. Waddill - Director	Grant or award	Common Stock	16,733	$22.99	$385K
Dec 18, 2024	Mauro Ferrari - Director	Grant or award	Common Stock	16,733	$22.99	$385K
Dec 18, 2024	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	12,653	$20.52	$260K
Dec 18, 2024	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	8,260	$21.74	$180K
Dec 18, 2024	Christopher Richard Anzalone - Officer	Open-market sale	Common Stock	5,799	$22.12	$128K
Dec 18, 2024	Christopher Richard Anzalone - Officer	Grant or award	Common Stock	100,000	$0.00	-
Dec 18, 2024	Michael S. Perry - Director	Grant or award	Common Stock	16,733	$22.99	$385K
Dec 18, 2024	Adeoye Y. Olukotun - Director	Grant or award	Common Stock	16,733	$22.99	$385K
Dec 16, 2024	Victoria Vakiener - Director	Open-market sale	Common Stock	8,994	$21.91	$197K
Dec 16, 2024	William D. Waddill - Director	Open-market sale	Common Stock	3,748	$21.90	$82K
Dec 17, 2024	William D. Waddill - Director	Open-market sale	Common Stock	3,747	$22.04	$83K
Dec 16, 2024	Douglas B. Given - Director	Open-market sale	Common Stock	5,000	$21.90	$110K
Dec 17, 2024	Douglas B. Given - Director	Open-market sale	Common Stock	547	$22.04	$12K

Recent ARWR Form 8-K filings

Read ARWR company news

Aug 4, 2026Item 2.02, 9.01

Read the filing on SEC EDGAR

Jun 16, 2026Item 5.02, 9.01

Read the filing on SEC EDGAR

May 7, 2026Item 2.02, 9.01

Read the filing on SEC EDGAR

Mar 20, 2026Item 5.07, 9.01

Read the filing on SEC EDGAR

Recent ARWR Form 144 notices of proposed sale

An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.

Filed	Filer	Relationship	Shares	Market value	Notice
Aug 18, 2026	Adeoye Olukotun	Director	2,000	$174K	View on EDGAR
Aug 18, 2026	Michael Perry	Director	11,600	$1.01M

ARWR insider trading FAQ

What is the latest insider trade for ARWR?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had 2 insider filings in the last 90 days, with the most recent on 2026-08-20. The full record for ARWR runs to 25 Form 4 filings, the earliest from 2024-12-18. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying ARWR stock?

No insider purchases of ARWR were filed in the last 90 days.

How many insiders are selling ARWR stock?

2 insider sales of ARWR were filed in the last 90 days, totaling $1.19M.

Where can I see ARWR SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects ARWR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Aug 20, 2026 - Adeoye Y. Olukotun view on EDGAR
Aug 20, 2026 - Michael S. Perry view on EDGAR
Jun 18, 2026 - Matthew Gregory Cohen view on EDGAR
May 14, 2026 - Hongbo Lu view on EDGAR
Apr 24, 2026 - Daniel Joseph Apel view on EDGAR
Apr 24, 2026 - James C. Hamilton view on EDGAR
Mar 9, 2026 - James C. Hamilton view on EDGAR
Dec 16, 2025 - Christopher Richard Anzalone view on EDGAR
Dec 1, 2025 - Mauro Ferrari view on EDGAR

Related companies with recent insider activity

Learn more

Insider selling: signal or noise?: Why most insider sales are routine, and the few patterns worth a second look.
Form 144 vs Form 4: A Form 144 announces a planned sale; the Form 4 reports it after it happens.
Insider activity in Health Care: Where ARWR's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow ARWR with a 7-day demo

ARWR on your watchlist
Every ARWR Form 4 filing on record
Up to 3 months of ARWR price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Open-market sale

13,600

$1.19M

Date

Insider

Transaction

Security

Price

Value

Aug 18, 2026

Adeoye Y. Olukotun - Director

Open-market sale

Common Stock

2,000

$86.96

$174K

Aug 18, 2026

Michael S. Perry - Director

Open-market sale

Common Stock

11,600

$87.30^{footnote F1}

$1.01M

Footnote F1 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR

Jun 15, 2026

Matthew Gregory Cohen - Director

Grant or award

Common Stock

11,882^{footnote F1}

$0.00

Footnote F1 (shares): Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years.

May 12, 2026

Hongbo Lu - Director

Open-market sale

Common Stock

2,970

$76.88

$228K

Apr 22, 2026

Daniel Joseph Apel - Officer

Open-market sale

Common Stock

3,208^{footnote F2}

$70.11^{footnote F3}

$225K

Apr 22, 2026

Daniel Joseph Apel - Officer

Open-market sale

Common Stock

1,157^{footnote F2}

$70.45^{footnote F5}

$82K

Apr 22, 2026

Daniel Joseph Apel - Officer

Open-market sale

Common Stock

8,730^{footnote F2}

$71.92^{footnote F6}

$628K

Footnote F2 (shares): Partial disposition of shares to satisfy tax withholding obligations.
Footnote F3 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR
Footnote F5 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR
Footnote F6 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $71.55 to $71.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR

Apr 23, 2026

James C. Hamilton - Officer

Open-market sale

Common Stock

10,000

$75.00^{footnote F2}

$750K

Footnote F2 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR

Mar 5, 2026

James C. Hamilton - Officer

Open-market sale

Common Stock

10,000

$64.19^{footnote F2}

$642K

Footnote F2 (price): The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.80 to $64.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead… Full note on SEC EDGAR

Dec 12, 2025